HSP-IT Capsule SR is a combination medication containing Rabeprazole 20 mg and Itopride 150 mg, formulated for sustained release to provide effective management of gastrointestinal disorders. Rabeprazole, a proton pump inhibitor, acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion and promoting ulcer healing. Itopride, a prokinetic agent, enhances gastrointestinal motility by antagonizing dopamine D2 receptors and inhibiting acetylcholinesterase activity, facilitating gastric emptying and alleviating symptoms such as bloating, nausea, and early satiety. The combined action of Rabeprazole and Itopride in HSP-IT Capsule SR is particularly beneficial in treating conditions like gastroesophageal reflux disease (GERD), functional dyspepsia, and peptic ulcer disease where both acid suppression and improved motility are required. The sustained-release formulation ensures prolonged therapeutic effect, improving patient compliance by reducing dosing frequency. HSP-IT Capsule SR should be used under medical supervision, considering contraindications such as hypersensitivity to its components, and with caution in patients with hepatic or renal impairment. Common adverse effects may include headache, diarrhea, or abdominal discomfort. This combination therapy offers a comprehensive approach to managing upper gastrointestinal symptoms by targeting multiple pathophysiological mechanisms.